In a report released today, Tobias Gottschalt from Independent Research maintained a Sell rating on Qiagen (QGEN – Research Report), with a price target of EUR36.00. The company’s shares closed last Thursday at $50.48.
According to TipRanks.com, Gottschalt is ranked #6045 out of 7021 analysts.
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $58.40.
Based on Qiagen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $443 million and net profit of $89.76 million. In comparison, last year the company earned revenue of $382 million and had a net profit of $44.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.